Alector's shares plunged in after-hours trading as their Alzheimer drug candidate, AL002, did not meet its phase 2 primary endpoint. The stock dropped 33.6% to $2.63, prompting the company to discontinue the long-term study and reduce its workforce by 17%.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing